Chimeric antigen receptor T cells entered clinical trials over a decade ago and have shown unprecedented efficacy in patients with various hematologic malignancies.
The benefits of CAR T cell therapies have been greatest in patients with an aggressive type of B cell non-Hodgkin lymphoma known as diffuse large B cell lymphoma . However, modern miracles are limited, and unfortunately, ~60% of patients with DLBCL ultimately progress after anti-CD19 CAR T cell therapy
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: